Psoriasis is a common chronic autoimmune skin disorder with T-cell mediated multifunctional complex pathogenesis along with genetic predisposition. Conventionally, many therapies are available for the management of psoriasis, but they have limited efficacy due to higher side effects. Over the last decade, one of the major efforts in psoriasis research has been made for the development of drug molecules by understanding the potential biomolecules/biomarkers associated with psoriasis. This approach aims to provide selective immunologically directed intervention with fewer side effects than conventional therapies. The present review aims to give an exhaustive account on various biomarkers including oxidative stress, peptide, biochemical and gene markers responsible for keratocyte hyper proliferation, inflammatory responses and abnormal differentiation in psoriasis. Effective targeting of these over expressed biomarkers can serve as the novel tool for anti-psoriatic drug development. In addition, this review also gives insights into several novel biomarkers targeted drugs under pre-clinical and clinical investigation or have been registered by FDA for psoriasis management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/157016312799304516 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers of Extracellular Matrix Fragments in Patients with Psoriasis.
Int J Mol Sci
December 2024
Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, 2900 Hellerup, Denmark.
Blood-based extracellular matrix (ECM) fragments have been identified as potential pharmacologic biomarkers in spondyloarthritis and diagnostic biomarkers in psoriatic arthritis and psoriasis vulgaris. This study aimed to explore whether ECM fragments can differentiate patients with psoriasis from healthy controls (HC) and determine their potential as biomarkers for response to treatment in psoriasis. The study population included 59 patients with moderate to severe psoriasis, not receiving systemic anti-psoriatic treatment at inclusion, and 52 HC matched by age, sex, and BMI.
View Article and Find Full Text PDFTopical Application of Dipyridamole and Roflumilast Combination Nanoparticles Loaded Nanoemulgel for the Treatment of Psoriasis in Rats.
Int J Nanomedicine
December 2024
Laboratory of Chemical, Galenic and Pharmacological Development of Medicines (LR12ES09), Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.
Background: Phosphodiesterase-4 is an enzyme that regulates immune responses and contributes to the development of psoriasis. Dipyridamole and roflumilast function as phosphodiesterase-4 inhibitors, reducing pro-inflammatory cytokine expression. The aim was to evaluate the anti-psoriatic effect of the topical administration of dipyridamole and roflumilast nanoemulgel combination on imiquimod-induced psoriasiform skin inflammation in rats.
View Article and Find Full Text PDFContemplating Novel W/O Emulsion Based Gel for Anti-Psoriatic Activity of Tofacitinib in Imiquimod-Induced Balb/C Mice Model.
AAPS PharmSciTech
December 2024
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India.
Article Synopsis
- Tyrosine kinase inhibitors like tofacitinib (TCB) are effective in treating psoriasis, and this study aims to enhance TCB's effectiveness while minimizing side effects through a new topical emulgel formulation.
- The emulgel was created by combining TCB with various ingredients, resulting in a formulation with ideal viscosity, firmness, and controlled release of the drug over 24 hours.
- The new TCB-emulgel showed significantly improved anti-psoriatic effects in a mouse model, reducing psoriasis severity scores and inflammation markers compared to existing treatments, supporting its potential for clinical use in managing psoriasis.
Hyaluronan-Cholesterol nanogels embedding betamethasone for the treatment of skin inflammatory conditions.
Int J Pharm
January 2025
Departments of Drug Chemistry and Technologies, Sapienza University of Rome, P.le Aldo Moro 5, Rome 00185, Italy. Electronic address:
Topical application of the glucocorticoid betamethasone (BM) is a common treatment for inflammatory-related skin diseases, such as psoriasis. However, enhancing its bioavailability remains challenging due to poor skin permeability. Herein, we developed and evaluated hyaluronan-cholesterol (HACH) based nanohydrogel systems (NHs) and NHs-Carbopol formulation for dermal delivery of BM.
View Article and Find Full Text PDFBackground: Psoriasis is a chronic, autoimmune, T-cell-mediated inflammatory disease with an "onset-remission-recurrence" pattern, and is managed symptomatically, therefore the need for treatment is usually lifelong.
Primary Study Objective: This study aimed to evaluate the efficacy of Majoon and Tila Baras-e-Aswad, two combination formulations, consisting of herbal, mineral, and animal drugs (antioxidants, anti-psoriatic, antihistaminic, antipruritic, and skin protection with healing activities), prescribed for the treatment of Baras-e-Aswad, having a plaque psoriasis-like diagnosis in Unani medicine.
Methods/design: Open-label single-arm and single-center clinical study with pre-and post-treatment analysis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!